MSK Immuno-Oncology for the Translational Researcher Short Course

MSK 斯隆免疫肿瘤学转化研究人员短期课程

• 批准号: 9904998
• 负责人: Ushma Neill
• 金额: $ 34.32万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9904998
• 关键词: Antibody Therapy; Awareness; Biological Markers; Blocking Antibodies; Cancer Biology; Caring; Cell Therapy; Clinic; Clinical; Clinical Trials; Clinical Trials Design; Communities; Dedications; Development; Diagnostic; Diagnostic radiologic examination; Education; Educational workshop; Ensure; Exposure to; Eye; Faculty; Fostering; Foundations; Funding; Generations; Goals; Hematologic Neoplasms; Immunocompetent; Immunologics; Immunology; Immunooncology; Immunotherapeutic agent; Immunotherapy; Investments; Journals; Knowledge; Learning; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Mentors; Mentorship; Modernization; Needles; New York; Oncologist; Participant; Patients; Perception; Physicians; Research; Research Personnel; Role; Science; Scientist; Shapes; T-Lymphocyte; Techniques; Technology; Therapeutic; Therapeutic Agents; Training; Translational Research; anti-PD-L1 antibodies; anticancer research; arm; base; cancer education; cancer therapy; clinical application; clinical care; clinical practice; design; education research; experience; immune checkpoint blockade; improved; innovation; insight; interest; lectures; lens; next generation; novel; novel therapeutics; programmed cell death protein 1; programs; recruit; skills; tool; training opportunity; translational scientist; trial design; tumor immunology

UE5 MSK Immuno-Oncology for the Translational Researcher Short Course: Project Summary / Abstract The MSK Immuno-Oncology for the Translational Researcher Short Course (ITRSC) is a cancer education research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSK faculty. Program participants will attend a 3-day workshop onsite in New York, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology. We anticipate that for some of the ITRSC participants, this short course will be their first substantive exposure to immuno-oncology; for others, the deep dive into clinical aspects of complications, trial design and standards of therapy will be eye-opening. By providing them with a concentrated and intense exposure to immuno- oncology, we will ensure that they will have the proper understanding to apply their clinical and scientific skills to help develop novel research ideas and clinical trials with a better understanding of immunological concepts. A key goal of this program is to increase the junior faculty’s awareness of and interest in immuno-oncology research and give the perspective and concrete tools to tackle the most pertinent immuno-oncology questions at the interface between clinic and lab. Through strategic recruitment of NCI-funded scientists and physicians and exposure to carefully selected mentors and research topics, the ITRSC will provide a path toward development of cancer biologists capable of informing the vanguard of cancer biology and therapeutics. The ITRSC will enhance the participants’ knowledge about cancer, immunology, and their critical intersection by pursuing the following Specific Aims: 1. Develop a course to form a deep understanding of innovative immuno-oncology through lectures and hands on exposure to experimental techniques. 2. Provide NCI grantees additional mentorship and guidance in both clinical and translational immuno- oncology research in order to foster the trainees’ interest and engagement in academic immuno- oncology research. 3. Evaluate the efficacy of intensive training opportunities in shaping immuno-oncology research. Through the exposure that the ITRSC will enable, we expect to shape the faculty’s perception of immunology applied to cancer research and clinical practice such that many will pursue intensive research in this field.

UE5转化研究人员简短课程的UE5 MSK免疫肿瘤学：项目摘要 / 抽象的 转化研究人员短期课程（ITRSC）的MSK免疫肿瘤学是癌症教育 研究经验将使合格的初级NCI资助的教师了解肿瘤免疫学， 在当前基于免疫疗法的临床实践和最先进的翻译研究中 专家MSK教师。计划参与者将在纽约参加为期3天的现场研讨会，由他们带领 集中参与基本和临床免疫肿瘤研究。 ITRSC参与者也将有一个 寻求世界免疫肿瘤专家的额外心态和指导的机会。 我们预计对于某些ITRSC参与者，这条短期课程将是他们的第一个实质性曝光 进行免疫肿瘤学；对于其他人来说，深入研究并发症，试验设计和标准的临床方面 治疗将引人注目。通过为他们提供集中和强烈的免疫接触 肿瘤学，我们将确保他们将具有适当的理解来运用其临床和科学技能 帮助开发新颖的研究思想和临床试验，以更好地了解免疫学概念。 该计划的关键目标是提高初级教师对免疫肿瘤学的意识和兴趣 研究并提供透视和具体工具，以解决最相关的免疫肿瘤问题 在诊所和实验室之间的界面。通过战略招募NCI资助的科学家和医生 以及接触精心选择的导师和研究主题，ITRSC将为通往 能够开发能够告知癌症生物学和治疗先锋的癌症生物学家。 ITRSC将增强参与者对癌症，免疫学及其关键相交的知识 通过追求以下特定目标： 1。建立一门课程，通过讲座和 动手接触实验技术。 2。在临床和转化免疫方面向NCI受赠人提供其他心态和指导 肿瘤学研究是为了促进培训的兴趣和参与学术免疫 - 肿瘤学研究。 3。评估强化培训机会在塑造免疫肿瘤研究方面的效率。 通过接触ITRSC将启用的暴露，我们希望塑造教师对免疫学的看法 应用于癌症研究和临床实践，因此许多人将在该领域进行密集研究。